A Randomized Open-Label Multicenter Phase 3 Trial of Domvanalimab Zimberelimab and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously-Untreated Locally Advanced Unresectable or Metastatic Gastric Gastroesophageal Junction and Esophageal Adenocarcinoma

Brief description of study

This study is designed for patients who have Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma

This is a phase 3, randomized, open-label, multicenter trial for patients with previously-untreated locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma. Participants will be randomized to one of two study treatments: Domvanalimab, Zimberelimab and chemotherapy OR Nivolumab and chemotherapy.

Clinical Study Identifier: s22-00835

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.